Roivant Sciences Ltd. (NASDAQ:ROIV), a next-generation biopharmaceutical company dedicated to improving the delivery of healthcare to patients, announced today the commencement of a proposed underwritten public offering of $150,000,000 of common shares. Roivant expects to grant the underwriter a 30-day option to purchase up to $22.5 million of additional common shares. The offering is subject to market conditions and other factors, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Charles River Laboratories Provides Access To Relevant, Well-Characterized Pediatric PDX Collection For Oncology Research
Recently established regulatory guidelines make testing for pediatric indications a necessary step in oncology research and developmentCharles River Laboratories International, Inc. (NYSE:CRL) today announced the ability
